Recombinant Lucihormetica verrucosa Periviscerokinin-1

What is Lucihormetica verrucosa Periviscerokinin-1 and how does it differ from other insect neuropeptides?

Lucihormetica verrucosa Periviscerokinin-1 (LucVe-PVK-1) is an 11-amino acid neuropeptide with the sequence GSTGLIPFGRT found in the cockroach species Lucihormetica verrucosa . It belongs to the periviscerokinin family of neuropeptides that have been identified across several cockroach species, including Periplaneta americana, Gyna lurida, Gyna cafforum, and Lucihormetica subcincta .

The distribution pattern of PVK-1 differs significantly from other insect neuropeptides. In Periplaneta americana, for example, more than 90% of the total 8.2 pmol of PVK-1 is found in the abdominal ganglia and perisympathetic organs, with minimal presence in the cephalic neurohaemal system . This distinct distribution pattern suggests specialized functions compared to other neuropeptides. Unlike some related compounds, PVK-1 is not released by the cephalic neurohaemal system, as corpora cardiaca and corpora allata do not contain immunoreactive material .

What are the optimal storage conditions for recombinant Lucihormetica verrucosa Periviscerokinin-1?

For optimal preservation of recombinant Lucihormetica verrucosa Periviscerokinin-1, researchers should adhere to the following storage protocols:

For short-term storage, keep the recombinant protein at -20°C. For extended preservation, store at either -20°C or -80°C to maintain stability . Working aliquots can be maintained at 4°C for up to one week, but repeated freeze-thaw cycles should be strictly avoided as they can compromise the structural integrity and biological activity of the peptide .

When preparing for long-term storage, it is recommended to reconstitute the protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL and add glycerol to a final concentration of 5-50% (with 50% being standard practice) . The addition of glycerol prevents crystal formation during freezing, which can damage the protein structure. After reconstitution, the solution should be aliquoted into smaller volumes to minimize freeze-thaw cycles.

The shelf life is approximately 6 months for liquid preparations stored at -20°C/-80°C, while lyophilized forms maintain stability for approximately 12 months under the same storage conditions .

How can researchers confirm the authenticity of recombinant Lucihormetica verrucosa Periviscerokinin-1 in their samples?

Confirming the authenticity of recombinant Lucihormetica verrucosa Periviscerokinin-1 requires a multi-analytical approach. First, researchers should verify the molecular weight and purity through SDS-PAGE, where the purity should exceed 85% as indicated in product specifications .

For more definitive identification, mass spectrometry techniques are essential, particularly MALDI-TOF mass spectrometry, which was successfully employed in previous studies to confirm the presence of authentic PVK-1 in biological samples . When analyzing the recombinant protein, researchers should expect to identify both oxidized and non-oxidized forms, as observed in previous HPLC-separated extracts of cockroach nervous tissue .

Additionally, immunoassay techniques such as ELISA can be utilized with specific antisera against PVK-1. The high specificity of previously developed antisera has enabled quantification in unseparated tissue extracts with minimal cross-reactivity with other insect neuropeptides . When conducting such immunological verification, researchers should be aware that the recombinant protein might contain tags added during the manufacturing process, which could affect antibody recognition .

What are the recommended protocols for reconstituting recombinant Lucihormetica verrucosa Periviscerokinin-1 for experimental use?

For optimal reconstitution of recombinant Lucihormetica verrucosa Periviscerokinin-1, researchers should follow this detailed protocol:

• Centrifuge the vial briefly before opening to ensure all material is at the bottom of the container .

• Reconstitute the lyophilized protein in deionized sterile water to achieve a concentration between 0.1-1.0 mg/mL. Use freshly prepared, sterile water to prevent contamination or unwanted chemical interactions .

• For solutions intended for long-term storage, add glycerol to a final concentration of 5-50% (with 50% being the standard recommendation). The glycerol serves as a cryoprotectant to maintain protein stability during freeze-thaw cycles .

• Mix gently by inversion or slow vortexing at low speed. Avoid vigorous agitation that could cause protein denaturation.

• Allow the solution to stand at room temperature for 5-10 minutes to ensure complete solubilization.

• Aliquot the reconstituted protein into sterile microcentrifuge tubes in volumes appropriate for single-use applications to minimize freeze-thaw cycles.

• For experimental applications requiring buffer conditions different from simple aqueous solutions, perform a step-wise buffer exchange using dialysis or desalting columns to prevent protein precipitation or denaturation.

When preparing working dilutions for experiments, maintain the protein in appropriate buffers that mimic physiological conditions, typically phosphate-buffered saline (PBS) adjusted to pH 7.2-7.4 for most functional assays.

How can researchers design experiments to study the functional properties of recombinant Lucihormetica verrucosa Periviscerokinin-1?

Designing robust experiments to study the functional properties of recombinant Lucihormetica verrucosa Periviscerokinin-1 requires careful consideration of both in vitro and in vivo approaches:

In vitro functional assays:

• Receptor binding studies: Express potential receptor candidates in cell lines (such as HEK293 or CHO cells) and measure binding affinity of the recombinant PVK-1 using competitive binding assays with labeled ligands.

• Signal transduction analysis: Investigate second messenger systems (cAMP, calcium flux, etc.) activated by PVK-1 in receptor-expressing cells using FRET-based sensors or biochemical assays.

• Electrophysiological recordings: Apply the recombinant peptide to isolated neural tissues from cockroaches to record changes in membrane potentials or firing patterns, particularly focusing on abdominal ganglia where natural PVK-1 is predominantly found .

In vivo experimental approaches:

• Microinjection studies: Administer recombinant PVK-1 to live cockroaches and observe physiological and behavioral changes, focusing on systems known to be regulated by neuropeptides.

• Immunohistochemistry following functional assays: After conducting physiological experiments, perform tissue fixation and immunostaining to correlate functional outcomes with the binding sites of the recombinant protein.

• Comparative studies: Design experiments that compare the effects of recombinant LucVe-PVK-1 with those of related periviscerokinin peptides from other cockroach species to identify species-specific functional differences .

When designing these experiments, researchers should include appropriate controls, such as heat-inactivated peptide, scrambled peptide sequences, or other unrelated neuropeptides, to ensure specificity of observed effects.

What techniques are most effective for quantifying recombinant Lucihormetica verrucosa Periviscerokinin-1 in experimental samples?

For precise quantification of recombinant Lucihormetica verrucosa Periviscerokinin-1 in experimental samples, researchers should consider a tiered analytical approach:

Immunological methods:

• Enzyme-Linked Immunosorbent Assay (ELISA): Develop a sandwich ELISA using high-specificity antisera against PVK-1. Previous studies have demonstrated that specific antisera allow quantification of PVK-1 in unseparated tissue extracts without cross-reactivity with other insect neuropeptides . For recombinant protein, standard curves should be prepared using the same E. coli-expressed protein to account for possible differences from native peptides.

• Radioimmunoassay (RIA): While more complex to establish, RIA offers high sensitivity for quantification in complex biological matrices.

Chromatographic approaches:

• High-Performance Liquid Chromatography (HPLC): Develop a specific HPLC method that can distinguish between oxidized and non-oxidized forms of the peptide, as observed in previous studies . UV detection at 214 nm (peptide bond) and 280 nm (aromatic residues) can be used for quantification.

• Liquid Chromatography-Mass Spectrometry (LC-MS): For highest specificity and sensitivity, LC-MS/MS methods targeting specific fragment ions of the PVK-1 sequence (GSTGLIPFGRT) provide absolute quantification in complex matrices.

Mass spectrometry-based quantification:

• MALDI-TOF mass spectrometry with isotopically-labeled internal standards can provide accurate quantification, particularly useful when analyzing tissue samples .

• Multiple Reaction Monitoring (MRM) using triple quadrupole mass spectrometers offers excellent sensitivity and specificity for targeted quantification.

When selecting a quantification method, researchers should consider the expected concentration range, sample complexity, and required specificity. For most research applications, combining immunological screening (ELISA) with confirmation and precise quantification by LC-MS/MS provides the most reliable results.

How does recombinant Lucihormetica verrucosa Periviscerokinin-1 compare structurally and functionally with PVK-1 from other cockroach species?

Recombinant Lucihormetica verrucosa Periviscerokinin-1 shares the fundamental 11-amino acid sequence (GSTGLIPFGRT) with PVK-1 identified in other cockroach species, but exhibits important structural and functional distinctions . Comparative analysis reveals:

Structural comparisons:
The PVK-1 peptide has been identified across multiple cockroach species including Periplaneta americana, Gyna lurida, Gyna cafforum, Lucihormetica subcincta, and Lucihormetica grossei . Sequence conservation of the C-terminal pentapeptide (FPGRT) is typical across the periviscerokinin family, serving as the key functional motif for receptor binding, while N-terminal variations contribute to species-specific effects.

Recombinant production in E. coli may introduce minor structural differences from native peptides, particularly in post-translational modifications. Unlike native peptides that may undergo amidation or other modifications, recombinant peptides produced in bacterial systems typically lack these modifications unless specifically engineered.

Functional differences:
The distribution pattern of PVK-1 in Periplaneta americana (with over 90% located in abdominal ganglia and perisympathetic organs) suggests specialized neurological functions that may differ from patterns in Lucihormetica species . This distribution contrasts notably with other insect neuropeptides, indicating species-specific functional adaptations.

Hybridization studies between Lucihormetica verrucosa and Lucihormetica subcincta have shown that while these closely related species can produce hybrid offspring in specific cross directions (L. verrucosa female × L. subcincta male), the hybrids appear to have fertility limitations . These reproductive compatibility patterns suggest potential differences in neuropeptide signaling systems that may include variations in PVK-1 function or receptor interactions between species.

When designing comparative studies, researchers should account for these potential species-specific differences and consider using multiple assay systems to fully characterize functional variations.

What is known about the receptor systems and signaling pathways activated by Periviscerokinin-1 in insects?

The receptor systems and signaling pathways activated by Periviscerokinin-1 in insects represent a complex neuromodulatory network, though specific details for Lucihormetica verrucosa have not been fully elucidated. Based on research with related periviscerokinin peptides:

Receptor classification:
Periviscerokinin peptides typically bind to G-protein coupled receptors (GPCRs) belonging to the neuropeptide receptor family. These receptors generally contain seven transmembrane domains with an extracellular N-terminus that interacts with the C-terminal pentapeptide motif (FPGRT) of the PVK-1 peptide.

Signaling cascades:
Upon receptor binding, several downstream signaling pathways may be activated:

• The primary pathway often involves Gq protein activation, leading to phospholipase C stimulation, inositol trisphosphate (IP3) production, and subsequent calcium mobilization from intracellular stores.

• Alternative pathways may include activation of adenylyl cyclase and subsequent cAMP production, particularly in certain tissue types or under specific physiological conditions.

• The mobilized calcium can activate calcium-dependent protein kinases, leading to phosphorylation of target proteins and changes in cellular function.

Physiological effects:
The specific distribution of PVK-1 in the abdominal ganglia and perisympathetic organs (as observed in Periplaneta americana) suggests roles in:

• Modulation of visceral muscle contraction, particularly in the hindgut and other digestive structures .

• Potential regulation of water and ion balance, a function attributed to some related neuropeptides.

• Neuromodulatory effects on central pattern generators controlling rhythmic behaviors.

The absence of PVK-1 in the corpora cardiaca and corpora allata indicates it likely does not function as a classical neurohormone released by the cephalic neurohaemal system, distinguishing it from many other insect neuropeptides .

Further research using the recombinant Lucihormetica verrucosa PVK-1 is needed to definitively characterize its receptor interactions and downstream signaling effects.

How can researchers effectively use recombinant Lucihormetica verrucosa Periviscerokinin-1 in comparative studies with other insect neuropeptides?

Conducting rigorous comparative studies between recombinant Lucihormetica verrucosa Periviscerokinin-1 and other insect neuropeptides requires careful experimental design and standardized methodologies:

Experimental design considerations:

• Standardized preparation: Ensure all peptides being compared (including PVK-1 and other neuropeptides) are prepared and quantified using identical methods to minimize technical variables. Standardize concentrations on a molar basis rather than mass to account for molecular weight differences .

• Cross-reactivity testing: Before comparative experiments, validate the specificity of detection methods using a panel of related peptides. Previous studies have demonstrated that high-specificity antisera can distinguish PVK-1 without cross-reactivity with other insect neuropeptides .

• Parallel assays: Design experiments where multiple neuropeptides are tested simultaneously under identical conditions, rather than in sequential experiments that might introduce temporal variables.

Methodological approaches:

• Receptor binding competition assays: Use labeled reference ligands and test the ability of different neuropeptides to compete for receptor binding. This approach can reveal relative affinities and receptor selectivity profiles.

• Dose-response curves: Generate complete dose-response relationships for each peptide across a wide concentration range (typically 10^-12 to 10^-6 M) to accurately compare potency (EC50 values) and efficacy (maximum response).

• Cellular response profiling: Employ multiplexed assays measuring various second messengers (calcium, cAMP, etc.) to create comprehensive signaling fingerprints for each peptide.

• Tissue-specific functional assays: Compare effects on isolated tissues where neuropeptides are known to be active, such as the hyperneural muscle or hindgut preparations, measuring parameters like contraction amplitude and frequency.

• Distribution mapping: Use immunohistochemistry and mass spectrometry imaging to compare the anatomical distribution patterns of different neuropeptides, as distribution differences may indicate specialized functions .

Data analysis framework:

Create a standardized data matrix incorporating multiple parameters (potency, efficacy, tissue selectivity, receptor selectivity) to enable statistical clustering and principal component analysis. This approach can reveal relationships between structurally diverse neuropeptides that may not be apparent from single-parameter comparisons.

What are common challenges when working with recombinant Lucihormetica verrucosa Periviscerokinin-1 and how can they be addressed?

Researchers working with recombinant Lucihormetica verrucosa Periviscerokinin-1 may encounter several technical challenges that can impact experimental outcomes. Here are the most common issues and detailed methodological solutions:

Stability and degradation issues:

• Challenge: Peptide degradation during storage or experiment.

• Solution: Store reconstituted peptide in single-use aliquots with 50% glycerol at -80°C . Add protease inhibitors to experimental buffers. For particularly sensitive applications, validate peptide integrity before each experiment using HPLC or mass spectrometry.

Solubility and aggregation problems:

• Challenge: Poor solubility or aggregation in experimental buffers.

• Solution: Perform reconstitution in steps, first dissolving in a small volume of mildly alkaline buffer (pH 8.0) before diluting to working concentration. Filter solutions through 0.22 μm filters to remove any aggregates. If aggregation persists, try adding 0.1% BSA as a carrier protein or use low concentrations (0.01-0.05%) of non-ionic detergents like Tween-20.

Adsorption to labware:

• Challenge: Loss of peptide due to adsorption to plastic or glass surfaces.

• Solution: Pre-treat all containers with Sigmacote® or similar siliconizing agents. Alternatively, use low-binding microcentrifuge tubes and pipette tips. Include 0.1% BSA in stock solutions to reduce non-specific binding.

Batch-to-batch variability:

• Challenge: Inconsistent results between different lots of recombinant protein.

• Solution: Perform lot-specific validation using SDS-PAGE and mass spectrometry before beginning experiments . Create internal standards for quantitative assays and normalize experimental data to account for potential variations in activity.

Tag interference with functional assays:

• Challenge: Protein tags added during recombinant production may interfere with peptide function.

• Solution: If possible, select tag-free preparations or preparations with cleavable tags. When using tagged protein, include appropriate controls with the tag alone to distinguish tag-related effects from peptide-specific activity .

Oxidation effects:

• Challenge: Formation of oxidized forms affecting biological activity.

• Solution: Include reducing agents like DTT (0.1-1 mM) in storage buffers. Be aware that HPLC separation may reveal both oxidized and non-oxidized forms, as observed in previous studies . Design experiments to test the activity of both forms separately.

By anticipating these common challenges and implementing appropriate methodological solutions, researchers can significantly improve the reliability and reproducibility of experiments using recombinant Lucihormetica verrucosa Periviscerokinin-1.

What quality control measures should be implemented when working with recombinant Lucihormetica verrucosa Periviscerokinin-1?

Implementing comprehensive quality control measures when working with recombinant Lucihormetica verrucosa Periviscerokinin-1 is essential for ensuring experimental reliability and reproducibility. A systematic quality control workflow should include:

Initial characterization upon receipt:

• Purity assessment: Verify the purity meets or exceeds the specified 85% using SDS-PAGE with appropriate molecular weight markers . Consider silver staining for enhanced sensitivity.

• Identity confirmation: Validate the peptide identity using mass spectrometry, specifically MALDI-TOF MS or LC-MS/MS, to confirm the correct amino acid sequence (GSTGLIPFGRT) .

• Tag verification: If applicable, confirm the presence and nature of any expression tags that might be present using Western blot with tag-specific antibodies .

Pre-experimental validation:

• Concentration verification: Determine the actual concentration using quantitative amino acid analysis or BCA/Bradford assays calibrated with standards of similar peptide composition.

• Secondary structure analysis: For applications where protein folding is critical, perform circular dichroism (CD) spectroscopy to assess secondary structural elements.

• Oxidation state assessment: Analyze the oxidation state using reverse-phase HPLC to distinguish between oxidized and non-oxidized forms, as both may be present in preparations .

Routine quality checks during experimental use:

• Stability monitoring: Implement a regular testing schedule for stored aliquots, checking for degradation using HPLC or gel electrophoresis every 3-6 months.

• Functional validation: Develop a standardized bioassay relevant to your research to verify biological activity before critical experiments.

• Reference standard comparison: Maintain a reference standard from a well-characterized batch and perform comparative analysis against this standard when using new lots.

Documentation and reporting standards:

• Certificate of analysis review: Carefully review supplier documentation for each batch, noting key parameters such as purity, production date, and lot-specific characteristics .

• Batch tracking system: Implement a laboratory information management system to track peptide source, storage conditions, freeze-thaw cycles, and use in experiments.

• Quality control data repository: Maintain a centralized database of all quality control results to facilitate trend analysis and early detection of stability issues.

By systematically implementing these quality control measures, researchers can minimize variability and ensure that experimental outcomes reflect the true biological activities of recombinant Lucihormetica verrucosa Periviscerokinin-1 rather than artifacts of sample quality.

What are promising research applications for recombinant Lucihormetica verrucosa Periviscerokinin-1 in insect neurobiology?

Recombinant Lucihormetica verrucosa Periviscerokinin-1 offers several promising avenues for advancing insect neurobiology research:

Neural circuit mapping and modulation:
The predominant localization of PVK-1 in abdominal ganglia and perisympathetic organs in cockroaches suggests specialized roles in specific neural circuits . Recombinant PVK-1 labeled with fluorescent tags could serve as a tool for mapping these circuits, particularly when combined with electrophysiological recordings to correlate anatomical distribution with functional effects. This approach could reveal how PVK-1 modulates central pattern generators controlling rhythmic behaviors such as ventilation or locomotion.

Comparative neuroendocrinology:
The distinct distribution pattern of PVK-1 compared to other neuropeptides offers an opportunity to investigate evolutionary adaptations in neuromodulatory systems across insect species . Systematic studies comparing the effects of recombinant PVK-1 from Lucihormetica verrucosa with those from other cockroach species could provide insights into how neuropeptide functions have diversified during evolution. This is particularly relevant given the observed reproductive isolation between closely related species like Lucihormetica verrucosa and Lucihormetica subcincta .

Development of selective receptor ligands:
The recombinant peptide could serve as a template for developing modified analogs with enhanced receptor selectivity or stability. Structure-activity relationship studies, where specific amino acids in the PVK-1 sequence are systematically modified, could identify the minimal functional motifs and lead to the development of receptor-specific agonists or antagonists. These tools would be valuable for dissecting the contributions of PVK-1 signaling to specific physiological processes.

Hybrid species neurophysiology:
The documented ability to produce hybrid offspring between Lucihormetica verrucosa females and Lucihormetica subcincta males presents a unique opportunity to study how neuropeptide systems function in hybrid contexts. Comparing the responsiveness of neural tissues from parent species and their hybrids to recombinant PVK-1 could provide insights into the molecular basis of species-specific behaviors and potentially explain the reduced fertility observed in hybrids.

Integration with genomic and transcriptomic approaches:
Combining functional studies using recombinant PVK-1 with analysis of receptor expression patterns obtained through transcriptome sequencing could provide a comprehensive understanding of PVK-1 signaling networks across different developmental stages and physiological conditions.

How might advanced imaging techniques enhance our understanding of Periviscerokinin-1 function in insect nervous systems?

Advanced imaging techniques offer unprecedented opportunities to elucidate the complex functions of Periviscerokinin-1 in insect nervous systems:

These techniques could reveal:

• The precise synaptic localization of PVK-1 receptors relative to other synaptic components

• Nanoscale clustering patterns that might indicate specialized signaling microdomains

• Co-localization with other neuropeptide receptors at sub-diffraction resolution

Functional imaging with genetically-encoded reporters:
Combining recombinant PVK-1 application with genetically-encoded calcium indicators (GECIs) like GCaMP or voltage indicators (GEVIs) would allow real-time visualization of neural activity modulated by this neuropeptide. This approach could map the functional connectivity of PVK-1-responsive circuits and reveal temporal dynamics of signaling cascades.

Specific applications include:

• Whole-ganglion calcium imaging to identify all neurons responding to PVK-1 application

• Targeted expression of GECIs in identified neuronal populations to monitor circuit-specific responses

• Dual-color imaging to simultaneously track multiple signaling components (e.g., calcium and cAMP)

Correlative light and electron microscopy (CLEM):
This hybrid approach would enable researchers to first identify PVK-1-containing structures using fluorescence microscopy, then examine their ultrastructure with electron microscopy. This technique could reveal how PVK-1-containing vesicles are distributed within neurons and at synaptic terminals, providing insights into release mechanisms.

Expansion microscopy:
This technique physically expands biological specimens using swellable polymers, achieving effective super-resolution imaging with conventional microscopes. Applied to insect ganglia, expansion microscopy could reveal fine details of PVK-1 distribution in neural processes that are too densely packed to resolve with conventional methods.

Light-sheet microscopy for whole-organism imaging:
For developmental studies or whole-body mapping, light-sheet microscopy offers rapid 3D imaging of entire insect nervous systems with minimal phototoxicity. This approach could track the development of PVK-1-expressing neurons throughout metamorphosis or map complete distribution patterns across species for evolutionary comparisons.

By combining these advanced imaging approaches with the application of recombinant Lucihormetica verrucosa Periviscerokinin-1, researchers can move beyond simple localization studies to understand the dynamic functions of this neuropeptide in modulating neural circuit activity and behavior.

What potential exists for using recombinant Lucihormetica verrucosa Periviscerokinin-1 in comparative evolutionary studies?

Recombinant Lucihormetica verrucosa Periviscerokinin-1 presents valuable opportunities for investigating evolutionary aspects of neuropeptide signaling systems across insect lineages:

Molecular evolution of neuropeptide structure and function:
The 11-amino acid sequence of Lucihormetica verrucosa PVK-1 (GSTGLIPFGRT) can serve as a reference point for comparative analyses with periviscerokinin peptides from other cockroach species and more distantly related insects . Using the recombinant peptide in standardized functional assays across species would allow researchers to correlate sequence divergence with functional changes, providing insights into which residues are under evolutionary constraint versus those that can tolerate substitutions.

Specific approaches include:

• Systematic functional comparison of recombinant PVK-1 variants from multiple cockroach species (Periplaneta americana, Gyna lurida, Gyna cafforum, Lucihormetica subcincta) in identical bioassays

• Reconstruction of ancestral PVK sequences using phylogenetic methods and testing their functional properties

• Correlation of peptide conservation patterns with species' ecological niches and physiological adaptations

Receptor co-evolution studies:
The evolution of neuropeptides is intrinsically linked to that of their receptors. Comparing the binding properties of recombinant Lucihormetica verrucosa PVK-1 to receptors cloned from different insect species could reveal co-evolutionary patterns and potentially identify instances of receptor-ligand specificity shifts. This is particularly relevant in light of the reproductive isolation observed between closely related species like Lucihormetica verrucosa and Lucihormetica subcincta .

Hybrid species neurophysiology:
The documented ability to produce viable but possibly infertile hybrids between Lucihormetica verrucosa females and Lucihormetica subcincta males offers a unique experimental system . Testing neural tissues from parent species and their hybrids for responsiveness to recombinant PVK-1 could reveal how divergent neuropeptide systems interact in hybrid contexts and potentially contribute to reproductive isolation mechanisms.

Transcriptome-informed evolutionary analyses:
Combining functional studies using recombinant PVK-1 with comparative transcriptomics across species can reveal evolutionary patterns in the broader signaling networks that include PVK-1. Previous work has established transcriptome analysis methods for insect nervous systems that could be applied to this question, such as the desert locust central nervous system transcriptome .

Quantitative distribution analysis across species:
The distinct distribution pattern of PVK-1 in Periplaneta americana (with over 90% concentrated in abdominal ganglia and perisympathetic organs) provides a quantitative trait that can be compared across species . Using identical quantification methods with recombinant PVK-1 as a standard, researchers could determine whether this distribution pattern is conserved or divergent across cockroach lineages, potentially correlating distribution changes with behavioral or physiological adaptations.

Through these comparative evolutionary approaches, recombinant Lucihormetica verrucosa Periviscerokinin-1 could serve as a powerful tool for understanding how neuropeptide signaling systems diversify and adapt throughout insect evolution.